Gritstone’s goal is to develop groundbreaking immunotherapies for cancers and infectious diseases. Our approach focuses on generating a therapeutic immune response in these patients by unleashing the natural power of a patient’s immune system to recognize and destroy tumors or virally infected cells. It is well-established that one fundamental driver of an effective immune response is T cell recognition of abnormal cells and the proliferation of sufficient quantities of T cells to drive a potent attack against these cells, whether they are cancerous or virally infected. Inspired by this, we developed two platforms: 1) EDGE™, a best-in-class artificial intelligence driven platform to accurately identify T cell targets; and 2) unique delivery systems designed to stimulate the immune system and drive generation of T cells and neutralizing antibodies (nAbs) against the selected targets. Through these platforms, we have developed a portfolio of immunotherapies designed to effectively instruct the immune system to recognize and attack these targets. We believe that activating and directing the immune system in this unique way can offer an important opportunity to extend the benefits of immunotherapy to more patients.Read More
What is a Tumor Antigen?
A small protein on the surface of a tumor cell that functions as the target for T cell mediated tumor death.
Antigens restricted to a certain normal cell type or lineage
Shared Tumor-Associated Antigens
Antigens present in normal cells and overexpressed in cancer cells
Shared Tumor-Specific Antigens
Antigens found in testis and tumor tissue that are functionally tumor specific
Antigens derived from mutated proteins in tumor cells